泓博医药
(301230)
| 流通市值：55.68亿 | | | 总市值：61.90亿 |
| 流通股本：1.63亿 | | | 总股本：1.81亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 550,795,701.14 | 364,406,306.14 | 172,285,876.53 | 688,350,863.65 |
| 营业收入 | 550,795,701.14 | 364,406,306.14 | 172,285,876.53 | 688,350,863.65 |
| 二、营业总成本 | 534,249,866.2 | 348,643,419.8 | 159,696,084.51 | 655,923,295.42 |
| 营业成本 | 402,499,441.62 | 262,736,731.31 | 117,291,172.53 | 499,634,937.09 |
| 税金及附加 | 1,050,871.25 | 639,972.27 | 327,403 | 2,005,368.46 |
| 销售费用 | 10,883,910.15 | 7,363,927.4 | 3,128,969.66 | 13,569,256.13 |
| 管理费用 | 75,639,516.22 | 49,597,060.7 | 24,460,125.35 | 97,444,786.91 |
| 研发费用 | 33,111,065.12 | 20,906,941.98 | 10,743,761.5 | 37,148,768.17 |
| 财务费用 | 11,065,061.84 | 7,398,786.14 | 3,744,652.47 | 6,120,178.66 |
| 其中:利息费用 | 5,392,107.28 | 3,687,962.65 | 1,913,932.19 | 8,288,635.54 |
| 其中:利息收入 | 1,167,738.14 | 594,933.18 | 291,164.21 | 1,502,822.23 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,229,184.43 | 8,792,384.73 | 11,481,297.38 | 6,996,140.63 |
| 加:投资收益 | 22,056,711.8 | 11,631,711.8 | 6,807,055.73 | 105,380.53 |
| 资产处置收益 | - | - | - | 41,517.55 |
| 资产减值损失(新) | -16,271,009.96 | -8,429,343.94 | -5,434,496.52 | -11,886,307 |
| 信用减值损失(新) | -3,653,706.91 | -1,826,517.84 | 499,408.45 | -4,130,781.85 |
| 其他收益 | 8,015,994.67 | 5,540,488.56 | 455,561.28 | 5,067,576.86 |
| 四、营业利润 | 29,923,008.97 | 31,471,609.65 | 26,398,618.34 | 28,621,094.95 |
| 加:营业外收入 | 35,362.59 | 24,858.69 | 6,158.69 | 22,804.41 |
| 减:营业外支出 | 1,429,667.07 | 1,361,984.76 | 420,015.21 | 327,013.66 |
| 五、利润总额 | 28,528,704.49 | 30,134,483.58 | 25,984,761.82 | 28,316,885.7 |
| 减:所得税费用 | -521,975.52 | 1,405,119.84 | 2,205,512.32 | -5,977,881.62 |
| 六、净利润 | 29,050,680.01 | 28,729,363.74 | 23,779,249.5 | 34,294,767.32 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 29,050,680.01 | 28,729,363.74 | 23,779,249.5 | 34,294,767.32 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 29,050,680.01 | 28,729,363.74 | 23,779,249.5 | 34,294,767.32 |
| 扣除非经常损益后的净利润 | 1,518,784.37 | 6,460,341.64 | 6,456,551.86 | 23,245,061.23 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.16 | 0.17 | 0.25 |
| (二)稀释每股收益 | 0.16 | 0.16 | 0.17 | 0.24 |
| 八、其他综合收益 | -42,621.55 | -3,995.55 | -114,466.4 | -17,625.94 |
| 归属于母公司股东的其他综合收益 | -42,621.55 | -3,995.55 | -114,466.4 | -17,625.94 |
| 九、综合收益总额 | 29,008,058.46 | 28,725,368.19 | 23,664,783.1 | 34,277,141.38 |
| 归属于母公司股东的综合收益总额 | 29,008,058.46 | 28,725,368.19 | 23,664,783.1 | 34,277,141.38 |
| 公告日期 | 2026-10-23 | 2026-08-28 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |